Global Solid Tumors Drugs Market 2016-2020

Table of Contents

PART 01: Executive summary

• Highlights

PART 02: Scope of the report

• Market overview
• Assumptions
• Top-vendor offerings

PART 03: Market research methodology

• Research methodology
• Economic indicators

PART 04: Introduction

• Key market highlights
• Markers used for diagnosis of solid tumors

PART 05: Cost analysis

PART 06: Pipeline portfolio

• Anticipated number of products with single and multiple indications by 2020

PART 07: Market landscape

• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by molecule type

• Small molecules
• Biologics

PART 09: Market segmentation by type of therapy

• Chemotherapy
• Hormone therapy
• Targeted therapy
• Immunotherapy

PART 10: Market segmentation by disease

• Global breast cancer drugs market
• Global NHL drugs market
• Global colorectal cancer drugs market
• Global NSCLC drugs market
• Global prostate cancer drugs market
• Global kidney cancer drugs market
• Global retinoblastoma drugs market
• Global cervical cancer market
• Global melanoma drugs market
• Global gastric cancer drugs market
• Global pancreatic cancer drugs market
• Global ovarian cancer drugs market
• Global liver cancer drugs market
• Global HL drugs market
• Global glioblastoma multiforme drugs market

PART 11: Geographical segmentation

• Solid tumors drugs market in Americas
• Solid tumors drugs market in EMEA
• Solid tumors drugs market in APAC

PART 12: Market drivers

• Patient assistance programs
• Exposure to risk factors
• Provision for rare diseases
• Promising pipeline
• Increase in prevalence of solid tumors

PART 13: Impact of drivers

PART 14: Market challenges

• Patent expiration of top-selling drugs
• Poor diagnosis and screening
• High cost of drugs
• Availability of chemotherapy and off-label drugs
• Stringent regulations

PART 15: Impact of drivers and challenges

PART 16: Market trends

• Increase in cancer awareness
• Emergence of targeted and combination therapies
• Emergence of biosimilars
• Joint ventures and partnerships for R&D
• Increase in use of brachytherapy

PART 17: Vendor landscape

• Competitive scenario
• Market share analysis 2015
• F. Hoffmann-La Roche
• Novartis
• Celgene
• Johnson & Johnson
• Pfizer
• BMS
• Other prominent vendors

PART 18: Appendix

• List of abbreviations

PART 19: Explore Technavio